Abstract
Currently, peptide-based cancer vaccines are being developed by many different groups, however, sufficient clinical outcomes have not yet been obtained. We have developed a personalized peptide vaccine for advanced cancer patients with different types of HLA-A locus. Personalization of the vaccination peptides from the candidate peptide pool was conducted by considering the HLA type of the patient and pre-existing levels of IgG for the candidate peptides. The personalized peptide vaccine for patients with hormone-refractory prostate cancer has been approved as an innovative therapy by the Ministry of Health, Labour and Welfare, Japan. Here, we describe the recent progress of the personalized peptide vaccine for patients with advanced cancers.
